stockrowCronos Group Inc.
CRON Healthcare Drug Manufacturers Specialty & Generic
Cronos Group Inc.’s revenue for fiscal 2025 (year ended December 2025) was $146.6 million, up 24.6% from fiscal 2024.
- Revenue
- +74.6%
- EPS
- −42.9%
- Free cash flow
- +179.6%
- Total debt
- −21.8%
Quarter to September 2026, against a year earlier
Follow CRON
Alert me
Cronos Group Inc. (CRON) P/E ratio
As of 5 November 2026, Cronos Group Inc. (CRON) trades at a P/E ratio of 21.9×. Over the past ten years it has ranged from 0.0× (March 2026) to 1,108× (January 2018); the current reading is higher than 79% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 20.5× and below the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 19.5× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 1.9× | — |
| FY2018 | 0.0× | — |
| FY2017 | 814× | 278.40% |
| FY2016 | 215× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 19.4× | 39.65% |
| Jun 2026 | 13.9× | (94.46%) |
| Mar 2026 | 251× | — |
| Dec 2025 | 0.0× | — |
| 35 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| XERS Xeris Biopharma Holdings, Inc. compare | n/m |
| HROW Harrow, Inc. compare | n/m |
| ALVO Alvotech compare | n/m |
| AMPH Amphastar Pharmaceuticals, Inc. compare | 12.3× |
| ANIP ANI Pharmaceuticals, Inc. compare | 13.3× |
| PAHC Phibro Animal Health Corporation compare | 14.0× |
| CRON Cronos Group Inc. | 21.9× |
| ETON Eton Pharmaceuticals, Inc. compare | 26.8× |
| PCRX Pacira BioSciences, Inc. compare | 38.4× |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)